MedTrace Logo

HER2 Vaccine for Locally Advanced Breast Cancer

NCT06949410 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-22

No results posted yet for this study

Summary

The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.

Conditions

Interventions

DRUG

HER2 Vaccine

MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines

Sponsors & Collaborators

  • Pravin T.P Kaumaya

    lead OTHER

Principal Investigators

  • Pravin Kaumaya, PhD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-12-31
Completion
2030-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06949410 on ClinicalTrials.gov